A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Trial Profile

A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs PIM 447 (Primary) ; Midazolam
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Novartis
  • Most Recent Events

    • 23 Mar 2017 Planned End Date changed from 28 Feb 2017 to 31 Dec 2018.
    • 23 Mar 2017 Planned primary completion date changed from 28 Feb 2017 to 31 Dec 2018.
    • 29 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top